Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib plus enzalutamide after prior ARPI progression in metastatic castration-resistant prostate cancer
2023-510536-37-00Phase 2Authorised
- Sponsor
- OncoSur
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of talazoparib and enzalutamide in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC), sponsored by OncoSur. Planned start Jul 2024; status: authorised.
02
Drugs
talazoparibenzalutamide
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2023-510536-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510536-37-00.